Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 5/20 | 0.59 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.58 |
| ▸ | MRGPRX4 | Q96LA9 | 4/20 | 0.57 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.54 |
| ▸ | KMO | O15229 | 1/20 | 0.50 |
| ▸ | TTR | P02766 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3127578 | 0.88 | LMNA (0.55) | PPARGAKR1C3MRGPRX4NR4A2KMO | |
| SCHEMBL27824670 | 0.88 | AKR1C3 (0.67) | PPARGAKR1C3MRGPRX4NR4A2KMO | |
| SCHEMBL27108465 | 0.85 | MRGPRX4 (0.62) | PPARGAKR1C3MRGPRX4KMOTTR | |
| SCHEMBL3891238 | 0.84 | NPC1 (0.52) | PPARGMRGPRX4RAB9ALMNAKDM4E | |
| SCHEMBL1750329 | 0.83 | PTGER4 (0.56) | TTRRAB9ALMNAMAPK1HTT | |
| SCHEMBL30147687 | 0.82 | AKR1C3 (0.73) | PPARGAKR1C3MRGPRX4NR4A2KMO | |
| SCHEMBL28043985 | 0.82 | AKR1C3 (0.73) | PPARGAKR1C3MRGPRX4NR4A2KMO | |
| SCHEMBL1042630 | 0.82 | AKR1C3 (0.79) | AKR1C3MRGPRX4NR4A2KMOTTR | |
| SCHEMBL29466776 | 0.82 | AKR1C3 (0.79) | AKR1C3MRGPRX4NR4A2KMOTTR | |
| SCHEMBL27144496 | 0.82 | HIF1A (0.53) | PPARGRAB9AKDM4ENPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062443-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMA INC (US) | 2026-03-05 | — | — | US | disclosed |
| WO-2024044098-A2 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| WO-2024044098-A2 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-02-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062443-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | C9, SSB, C1S | PPARG 3625/4885AKR1C3 547/4885MRGPRX4 643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.